Equities Analysts Offer Predictions for IRWD FY2026 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities researchers at Zacks Research boosted their FY2026 EPS estimates for shares of Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, January 8th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of $0.44 per share for the year, up from their prior forecast of $0.43. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share.

Separately, StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD opened at $3.77 on Monday. Ironwood Pharmaceuticals has a one year low of $3.06 and a one year high of $15.70. The company has a market cap of $603.31 million, a PE ratio of -125.67 and a beta of 0.34. The firm has a 50-day moving average of $4.05 and a 200-day moving average of $4.71.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $91.60 million during the quarter, compared to analyst estimates of $91.22 million. During the same period in the previous year, the business posted $0.12 EPS. The business’s revenue for the quarter was down 19.4% compared to the same quarter last year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its position in shares of Ironwood Pharmaceuticals by 0.7% during the 2nd quarter. Rhumbline Advisers now owns 365,701 shares of the biotechnology company’s stock valued at $2,384,000 after buying an additional 2,577 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Ironwood Pharmaceuticals by 74.3% in the second quarter. Victory Capital Management Inc. now owns 222,573 shares of the biotechnology company’s stock worth $1,451,000 after purchasing an additional 94,882 shares in the last quarter. Choreo LLC purchased a new position in shares of Ironwood Pharmaceuticals in the second quarter worth about $292,000. Daiwa Securities Group Inc. raised its position in shares of Ironwood Pharmaceuticals by 9.6% in the second quarter. Daiwa Securities Group Inc. now owns 55,770 shares of the biotechnology company’s stock valued at $364,000 after purchasing an additional 4,900 shares during the period. Finally, Headlands Technologies LLC lifted its stake in shares of Ironwood Pharmaceuticals by 127.7% during the 2nd quarter. Headlands Technologies LLC now owns 28,657 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 16,072 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.